Homepage Top Section2

An investigational antibody-drug conjugate (ADC), Teliso-V targets c-Met receptor tyrosine kinase that is overexpressed in tumours that include NSCLC. It is indicated to treat nonsquamous NSCLC patients with

AstraZeneca and Ionis Pharmaceuticals have closed a previously announced commercialisation agreement to develop and market experimental therapy, eplontersen, previously called IONIS-TTR-LRX. The deal was announced earlier this month.

The acquisition of 3DBT for the consideration amount is to be satisfied by the issuance to the sellers of a total of 33,900,003 consideration shares at 7.37 pence

A fully human biologic, Cosentyx is developed to directly target interleukin-17A (IL-17A), a cytokine. IL-17A is involved in the inflammation of plaque psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis

Trastuzumab is a monoclonal antibody intended to treat human epidermal growth factor receptor 2 positive (HER2-positive) breast and metastatic gastric cancers. The company aims to secure EMA approval

This brings the company’s total Series A funding raised to $107m. The financing was led by Third Rock Ventures and saw participation from Smilegate Investment, Schroders Capital, Alexandria

The long-acting injectable is indicated for use in adults and adolescents who are at risk of sexually acquiring HIV and test negative for HIV-1 before initiation. The regulatory

Boehringer Ingelheim has announced acceptance of a biologics license application (BLA) and granting of priority review by the US Food and Drug Administration (FDA) for spesolimab in treating

Novo Nordisk has announced plans to make more than $2.58bn (DKK17bn) investment to expand its manufacturing facilities in Kalundborg, Denmark. The company plans to construct three new manufacturing